CLS Therapeutics Advocates for Management Overhaul at Xenetic Biosciences (XBIO) Following Stockholder Opposition to Executive Compensation

Mar 22, 2024

∙ Paid

Key Summary:  On March 18, 2024, CLS Therapeutics, LLC, holding a 14% stake, sent a letter to the board's Corporate Secretary expressing dissatisfaction with the current management.

Market Cap: $7 million | Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform …

This post is for paid subscribers

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Snowball Research

CLS Therapeutics Advocates for Management Overhaul at Xenetic Biosciences (XBIO) Following Stockholder Opposition to Executive Compensation

This post is for paid subscribers